First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5672
Abstract: Introduction: Genomic alterations, including IGHV mutation status, are predictive for outcomes on chemoimmunotherapy in CLL. Here we report outcomes in subgroups by genomic alterations in patients (pts) treated with fixed-duration (FD) ibrutinib (Ibr) + venetoclax… read more here.
Keywords: pts treated; treated ibr; glow; ibr ven ... See more keywords